Mérieux Développement and Paladin Capital Group co-lead $55.5 million Series C financing into Inscripta, a leading company in the field of gene editing, in preparation for platform expansion and commercial launch.
Investment will accelerate development and commercialization of gene-editing tools including enzymes, reagents, instrumentation, and software San Francisco, Lyon and Boston, February 28, 2018 – Merieux Developpement and Paladin Capital Group announced the completion of a $55.5 million Series C funding into Inscripta, a leading gene-editing technology company, based in Boulder, CO and Pleasanton, CA. Additional […]